- Home
- VTLE vs CDNA Comparison
VTLE vs CDNA Comparison
Compare VTLE & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- CDNA
- Stock Information
- Founded
- VTLE 2006
- CDNA 1998
- Country
- VTLE United States
- CDNA United States
- Employees
- VTLE N/A
- CDNA 643
- Industry
- VTLE
- CDNA Medical Specialities
- Sector
- VTLE
- CDNA Health Care
- Exchange
- VTLE Nasdaq
- CDNA Nasdaq
- Market Cap
- VTLE 1.1B
- CDNA 1.2B
- IPO Year
- VTLE 2011
- CDNA 2014
- Fundamental
- Price
- VTLE $29.35
- CDNA $20.58
- Analyst Decision
- VTLE Hold
- CDNA Buy
- Analyst Count
- VTLE 10
- CDNA 8
- Target Price
- VTLE $44.13
- CDNA $27.17
- AVG Volume (30 Days)
- VTLE 703.6K
- CDNA 653.8K
- Earning Date
- VTLE 11-06-2024
- CDNA 11-04-2024
- Dividend Yield
- VTLE N/A
- CDNA N/A
- EPS Growth
- VTLE N/A
- CDNA N/A
- EPS
- VTLE 13.16
- CDNA N/A
- Revenue
- VTLE $1,862,465,000.00
- CDNA $312,775,000.00
- Revenue This Year
- VTLE $29.04
- CDNA $19.85
- Revenue Next Year
- VTLE $8.01
- CDNA $11.34
- P/E Ratio
- VTLE $2.24
- CDNA N/A
- Revenue Growth
- VTLE 26.94
- CDNA 5.26
- 52 Week Low
- VTLE $25.85
- CDNA $7.42
- 52 Week High
- VTLE $58.30
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- VTLE 42.51
- CDNA 41.46
- Support Level
- VTLE $28.34
- CDNA $21.97
- Resistance Level
- VTLE $32.02
- CDNA $25.84
- Average True Range (ATR)
- VTLE 1.27
- CDNA 1.28
- MACD
- VTLE -0.34
- CDNA -0.22
- Stochastic Oscillator
- VTLE 21.77
- CDNA 13.86
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.